Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:AstraZeneca
|
| gptkbp:acquisitionYear |
2012
|
| gptkbp:focusesOn |
small molecule therapeutics
gout treatment |
| gptkbp:foundedYear |
2002
|
| gptkbp:founder |
Barry D. Quart
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
lesinurad
|
| gptkbp:parentCompany |
gptkb:AstraZeneca
|
| gptkbp:researchArea |
gptkb:cancer
inflammatory diseases viral diseases |
| gptkbp:status |
gptkb:subsidiary
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RDEA
|
| gptkbp:website |
https://www.ardeabio.com/
|
| gptkbp:bfsParent |
gptkb:refametinib
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ardea Biosciences
|